Clinical Trial Update: A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib plus radiotherapy and S-1 for refractory or metastatic esophageal squamous cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Refractory or Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED